Yangtze River Pharmaceutical Group led Binhui Biopharm's $47m series B-plus round while Sigfox has been snapped up by UnaBiz for under $30m after raising over $300m.
Funding
China-based oncolytic virus therapeutics developer Binhui Biopharm has raised approximately $47m in a series B-plus round led by pharmaceutical group Yangtze River, DealStreetAsia reported yesterday. The round included medical product distributor Jointown Pharmaceutical Group, DNV Capital, Ming Capital and Hubei Provincial High-Tech Industry Investment Group.
Intigriti, the Belgium-based operator of an online bug bounty platform, received €21.1m ($22.5m) in series B funding today from investors including energy utility EnBW’s corporate venturing unit, EnBW New Ventures. Venture capital firm Octopus…
